MedTrace Logo

A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer

NCT02026921 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2014-01-03

No results posted yet for this study

Summary

A phase II single arm study of carboplatin and docetaxel in treatment of first sensitive relapse of epithelial ovarian, peritoneal or tubal cancer.

Hypothesis: Treatment with this combination in second line is safe and with a low frequency of neurologic side effect.

Conditions

  • Ovarian Epithelial Cancer Recurrent

Interventions

DRUG

Carboplatin

Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops

DRUG

Docetaxel

75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    lead OTHER

Principal Investigators

  • Gunnar B Kristensen, MD, PhD · NSGO-CTU

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2006-03-31
Completion
2008-12-31

Countries

  • Denmark
  • Finland
  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02026921 on ClinicalTrials.gov